Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204366) titled 'Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)' on Sept. 24.
Study Type: Observational
Primary Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Condition:
Myeloproliferative Disease
COVID - 19
Recruitment Status: Not recruiting
Date of First Enrollment: May 6, 2022
Target Sample Size: 219
Countries of Recruitment:
Italy
To know more, visit https://clinicaltrials.gov/study/NCT07204366
Published by HT Digital Content Services with permission from Health Daily Digest....